cholecalciferol and Urticaria

Observational reports have linked vitamin D with chronic urticaria, yet no randomized controlled trial has been conducted.. To determine whether high-dose vitamin D supplementation would decrease Urticaria Symptom Severity (USS) scores and medication burden in patients with chronic urticaria.. In a prospective, double-blinded, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks. All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine, and montelukast) and a written action plan. Data on USS scores, medication use, blood for 25-hydroxyvitamin D, and safety measurements were collected.. Triple-drug therapy decreased total USS scores by 33% in the first week. There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12. Compared with low treatment, the high treatment group demonstrated a trend (P = .052) toward lower total USS scores at week 12, which was driven by significant decreases in body distribution and number of days with hives. Beneficial trends for sleep quality and pruritus scores were observed with high vitamin D3. Serum 25-hydroxyvitamin D levels increased with high vitamin D3 supplementation, but there was no correlation between 25-hydroxyvitamin D levels and USS scores. There was no difference in allergy medication use between groups. No adverse events occurred.. Add-on therapy with high-dose vitamin D3 (4,000 IU/d) could be considered a safe and potentially beneficial immunomodulator in patients with chronic urticaria.. clinicaltrials.gov Identifier: NCT01371877.

Topics: Acetates; Adult; Aged; Cetirizine; Cholecalciferol; Chronic Disease; Cyclopropanes; Dietary Supplements; Disease Progression; Female; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ranitidine; Sulfides; Urticaria; Young Adult

Vitamin D plays a key role in the immune responses generated by lymphocytes and antigen-presenting cells. Decreased vitamin 25-hydroxyvitamin D (25(OH)D) levels have been implicated in several allergic disorders and association between 25(OH)D levels and chronic urticaria (CU) symptom scores has been evaluated in a few studies. This study was performed to assess the effects of vitamin D supplementation on the symptoms and quality of life scores in chronic spontaneous urticaria (CSU) and to vitamin D levels in CSU patients in comparison with controls.. Fifty-eight CSU patients and forty-five controls were included in the study. The patients were divided into two groups according to severity of the disease; as mild/moderate and severe urticaria. Serum 25-hydroxyvitamin D (25(OH)D) concentrations were measured in serum of CSU patients and compared with the control groups. In patients with 25(OH)D concentrations lower than 30 µg/L, 300 000 IU/month of vitamin D3 supplementation was added to standard therapy. The clinical improvement was evaluated after 3 months with urticaria activity score (UAS4) and Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).. Serum 25(OH)D concentration was significantly lower in CSU group compared to healthy subjects (p < 0.001). The prevalence of vitamin D deficiency (<20 (µg/L) and insufficiency (<30 µg/L) was significantly higher in CSU patients than control groups. In addition, 25(OH)D concentrations were significantly lower in both mild-moderate and severe CSU patients than those of the controls (p = 0.011 and p < 0.001, respectively). Ninety eight percent of patients (25(OH)D < 30 µg/L) were treated with vitamin D3 (300 000 IU/month) supplementation, and after 12 weeks, these patients showed significant improvements in UAS4 and CU-Q2oL scores.. This study support the contributing and beneficial effects of vitamin D in the treatment of CU. Replacement of vitamin D may provide improvement in both the severity of symptoms and the quality of life scores in these patients.

Topics: Adolescent; Adult; Aged; Case-Control Studies; Cholecalciferol; Chronic Disease; Dietary Supplements; Female; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires; Urticaria; Vitamin D; Vitamin D Deficiency; Vitamins; Young Adult

Topics: Anabolic Agents; Angioedemas, Hereditary; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Cholecalciferol; Complement C1 Inactivator Proteins; Complement C1 Inhibitor Protein; Dietary Supplements; Humans; Omalizumab; Recombinant Proteins; Sulfasalazine; Urticaria